trimebutine has been researched along with Cholera Infantum in 8 studies
Trimebutine: Proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trimebutine maleate is a prokinetic drug that hastens gastric emptying, by inducing the release of gastrointestinal agents such as motilin and gastrin." | 6.72 | The trimebutine effect on Helicobacter pylori-related gastrointestinal tract and brain disorders: A hypothesis. ( Boziki, M; Deretzi, G; Doulberis, M; Fludaras, I; Gavalas, E; Grigoriadis, N; Karafoulidou, E; Katsinelos, P; Kesidou, E; Koukoufiki, A; Kountouras, J; Liatsos, C; Papaefthymiou, A; Polyzos, SA; Simeonidou, C; Sofou, E; Taloumtzis, C; Theotokis, P; Touloumtzi, M; Vardaka, E, 2021) |
| " In the double-blind segment, 69 patients with chronic gastro-intestinal spasmodic conditions were allocated, according to a pre-set randomization table, to receive orally 3 daily doses of fenoverine (100 mg; 35 patients), trimebutine (150 mg; 14 patients) or placebo (20 patients) during an average of 8 days." | 5.06 | Fenoverine: a two-step, double-blind and open clinical assessments of its smooth muscle synchronizing effects. ( Bader, F, 1986) |
| "Trimebutine maleate has been used extensively, since the late 1960's, for the treatment of functional gastrointestinal disorders, including irritable bowel syndrome (IBS)." | 5.01 | Trimebutine: a state-of-the-art review. ( Salvioli, B, 2019) |
| "Trimebutine maleate is a prokinetic drug that hastens gastric emptying, by inducing the release of gastrointestinal agents such as motilin and gastrin." | 2.72 | The trimebutine effect on Helicobacter pylori-related gastrointestinal tract and brain disorders: A hypothesis. ( Boziki, M; Deretzi, G; Doulberis, M; Fludaras, I; Gavalas, E; Grigoriadis, N; Karafoulidou, E; Katsinelos, P; Kesidou, E; Koukoufiki, A; Kountouras, J; Liatsos, C; Papaefthymiou, A; Polyzos, SA; Simeonidou, C; Sofou, E; Taloumtzis, C; Theotokis, P; Touloumtzi, M; Vardaka, E, 2021) |
| "Trimebutine was prescribed in accordance with the instructions for medical use: orally, 300 mg twice per day for 28 days." | 1.62 | [Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study]. ( Andreev, DN; Maev, IV, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreev, DN | 1 |
| Maev, IV | 1 |
| Salvioli, B | 1 |
| Boziki, M | 1 |
| Grigoriadis, N | 1 |
| Papaefthymiou, A | 1 |
| Doulberis, M | 1 |
| Polyzos, SA | 1 |
| Gavalas, E | 1 |
| Deretzi, G | 1 |
| Karafoulidou, E | 1 |
| Kesidou, E | 1 |
| Taloumtzis, C | 1 |
| Theotokis, P | 1 |
| Sofou, E | 1 |
| Katsinelos, P | 1 |
| Vardaka, E | 1 |
| Fludaras, I | 1 |
| Touloumtzi, M | 1 |
| Koukoufiki, A | 1 |
| Simeonidou, C | 1 |
| Liatsos, C | 1 |
| Kountouras, J | 1 |
| Uchida, M | 1 |
| Iwata, T | 1 |
| Takagi, S | 1 |
| Sugiyama, Y | 1 |
| Ishitani, K | 1 |
| Honda, H | 1 |
| Sakai, Y | 1 |
| Bonzi, G | 1 |
| Reguzzoni, G | 1 |
| Rocca, F | 1 |
| Negri, L | 2 |
| Battocchio, F | 1 |
| Tacchettti, G | 1 |
| Bader, F | 1 |
| Camarri, E | 1 |
2 reviews available for trimebutine and Cholera Infantum
| Article | Year |
|---|---|
Trimebutine: a state-of-the-art review.
Topics: Animals; Digestive System Physiological Phenomena; Gastrointestinal Agents; Gastrointestinal Disease | 2019 |
The trimebutine effect on Helicobacter pylori-related gastrointestinal tract and brain disorders: A hypothesis.
Topics: Brain Diseases; Dysbiosis; Gastrointestinal Agents; Gastrointestinal Diseases; Gastrointestinal Micr | 2021 |
4 trials available for trimebutine and Cholera Infantum
| Article | Year |
|---|---|
[DA 3177 a new synthetic spasmolytic agent in the management of spastic-dyskinetic conditions of the digestive tract. Double-blind controlled clinical trial].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Gastrointestinal Dis | 1979 |
[Controlled evaluation of a new synthetic spasmolytic (DA 3177) in/pathology of the digestive system].
Topics: Adult; Aged; Benzoates; Cholecystitis; Clinical Trials as Topic; Colitis; Duodenitis; Female; Gastri | 1979 |
Fenoverine: a two-step, double-blind and open clinical assessments of its smooth muscle synchronizing effects.
Topics: Administration, Oral; Adult; Aged; Benzoates; Biliary Dyskinesia; Clinical Trials as Topic; Double-B | 1986 |
Fenoverine: smooth muscle synchronizer for the management of gastro-intestinal conditions. II. A trimebutine-controlled, double-blind, crossover clinical evaluation.
Topics: Adult; Aged; Benzoates; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Gast | 1986 |
2 other studies available for trimebutine and Cholera Infantum
| Article | Year |
|---|---|
[Efficacy of trimebutine in the treatment of functional gastrointestinal disorders: an observational multicenter study].
Topics: Abdominal Pain; Dyspepsia; Female; Gastrointestinal Diseases; Humans; Irritable Bowel Syndrome; Male | 2021 |
Effect of trimebutine maleate on the contractile response of the isolated ileum from diabetic rats.
Topics: Animals; Calcium; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Gastrointestinal Di | 1994 |